Table 3 Correlation between PFS and body composition parameters classifying patients based on the stage at the diagnosis. Significant values are in bold.

From: Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab

Parameter

Value

Stage I–III

Stage IV

HR (95% CI)

p-value

HR (95% CI)

p-value

BMI (kg/m2)

 < 25

Reference

 

Reference

 

 ≥ 25

0.56 (0.22–1.43)

0.223

1.73 (0.56–5.31)

0.337

SFI (cm2/m2)

Normal (< 82.97)

Reference

 

Reference

 

High (> 82.97)

1.23 (0.48–3.10)

0.666

4.57 (1.38–15.08)

0.013

SMI (cm2/m2)

Normal (> 40)

Reference

 

Reference

 

Sarcopenia (< 40)

1.30 (0.51–3.28)

0.581

0.64 (0.17–2.39)

0.512

VFI (cm2/m2)

Normal (< 37.1)

Reference

 

Reference

 

High (> 37.1)

0.53 (0.20–1.39)

0.195

2.80 (0.90–8.72)

0.075

TAFTI (cm2/m2)

Normal (< 118.82)

Reference

 

Reference

 

High (> 118.82)

1.14 (0.45–2.90)

0.775

8.56 (2.19–33.47)

0.002

  1. HR hazard ratio (from Cox regression models), CI confidence interval, BMI body mass index, SMI skeletal muscle index, SFI subcutaneous fat index, VFI visceral fat index, TAFTI Total abdominal fat index.
Back to article page